Cargando…
A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics
Ferroptosis, an emerging type of cell death found in the past decades, features specifically lipid peroxidation during the cell death process commonly by iron accumulation. Unfortunately, however, the direct delivery of iron species may trigger undesired detrimental effects such as anaphylactic reac...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457667/ https://www.ncbi.nlm.nih.gov/pubmed/34550744 http://dx.doi.org/10.1126/sciadv.abj8833 |
_version_ | 1784571149673299968 |
---|---|
author | Wu, Chenyao Liu, Zhonglong Chen, Zhixin Xu, Deliang Chen, Lisong Lin, Han Shi, Jianlin |
author_facet | Wu, Chenyao Liu, Zhonglong Chen, Zhixin Xu, Deliang Chen, Lisong Lin, Han Shi, Jianlin |
author_sort | Wu, Chenyao |
collection | PubMed |
description | Ferroptosis, an emerging type of cell death found in the past decades, features specifically lipid peroxidation during the cell death process commonly by iron accumulation. Unfortunately, however, the direct delivery of iron species may trigger undesired detrimental effects such as anaphylactic reactions in normal tissues. Up to date, reports on the cellular ferroptosis by using nonferrous metal elements can be rarely found. In this work, we propose a nonferrous ferroptosis-like strategy based on hybrid CoMoO(4)-phosphomolybdic acid nanosheet (CPMNS)–enabled lipid peroxide (LOOH) accumulation via accelerated Mo(V)-Mo(VI) transition, elevated GSH depletion for GPX4 enzyme deactivation, and ROS burst, for efficient ferroptosis and chemotherapy. Both in vitro and in vivo outcomes demonstrate the notable anticancer ferroptosis efficacy, suggesting the high feasibility of this CPMNS-enabled ferroptosis-like therapeutic concept. It is highly expected that such ferroptosis-like design in nanocatalytic medicine would be beneficial to future advances in the field of cancer-therapeutic regimens. |
format | Online Article Text |
id | pubmed-8457667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84576672021-10-01 A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics Wu, Chenyao Liu, Zhonglong Chen, Zhixin Xu, Deliang Chen, Lisong Lin, Han Shi, Jianlin Sci Adv Biomedicine and Life Sciences Ferroptosis, an emerging type of cell death found in the past decades, features specifically lipid peroxidation during the cell death process commonly by iron accumulation. Unfortunately, however, the direct delivery of iron species may trigger undesired detrimental effects such as anaphylactic reactions in normal tissues. Up to date, reports on the cellular ferroptosis by using nonferrous metal elements can be rarely found. In this work, we propose a nonferrous ferroptosis-like strategy based on hybrid CoMoO(4)-phosphomolybdic acid nanosheet (CPMNS)–enabled lipid peroxide (LOOH) accumulation via accelerated Mo(V)-Mo(VI) transition, elevated GSH depletion for GPX4 enzyme deactivation, and ROS burst, for efficient ferroptosis and chemotherapy. Both in vitro and in vivo outcomes demonstrate the notable anticancer ferroptosis efficacy, suggesting the high feasibility of this CPMNS-enabled ferroptosis-like therapeutic concept. It is highly expected that such ferroptosis-like design in nanocatalytic medicine would be beneficial to future advances in the field of cancer-therapeutic regimens. American Association for the Advancement of Science 2021-09-22 /pmc/articles/PMC8457667/ /pubmed/34550744 http://dx.doi.org/10.1126/sciadv.abj8833 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Wu, Chenyao Liu, Zhonglong Chen, Zhixin Xu, Deliang Chen, Lisong Lin, Han Shi, Jianlin A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
title | A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
title_full | A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
title_fullStr | A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
title_full_unstemmed | A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
title_short | A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
title_sort | nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457667/ https://www.ncbi.nlm.nih.gov/pubmed/34550744 http://dx.doi.org/10.1126/sciadv.abj8833 |
work_keys_str_mv | AT wuchenyao anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT liuzhonglong anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT chenzhixin anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT xudeliang anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT chenlisong anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT linhan anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT shijianlin anonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT wuchenyao nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT liuzhonglong nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT chenzhixin nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT xudeliang nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT chenlisong nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT linhan nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics AT shijianlin nonferrousferroptosislikestrategyforantioxidantinhibitionsynergizednanocatalytictumortherapeutics |